Fig. 3

Prognosis of CN-AML patients with TET2 mutation. a pooled ORs and 95%CI for CR rate(OR 0.803; P = 0.228). b pooled HRs and 95%CI for OS(HR 1.425; P < 0.001). c pooled HRs and 95%CI for EFS(HR 1.450; P < 0.001). d pooled HRs and 95%CI for EFS in patients under 65 years of age(HR 1.741; P = 0.005)